Is Mirati Therapeutics, Inc. overvalued or undervalued?

As of 5 October 2023, Mirati Therapeutics, Inc. has moved from fair to attractive based on recent evaluations. The company appears to be undervalued at this time. Key ratios indicate a price-to-earnings ratio of 15.2, a price-to-sales ratio of 4.5, and a debt-to-equity ratio of 0.3, which suggests a solid financial position relative to its earnings and sales.
In comparison to peers, Mirati's valuation metrics are more favorable than those of Blueprint Medicines Corporation, which has a price-to-earnings ratio of 20.1, and Iovance Biotherapeutics, Inc., with a price-to-sales ratio of 5.2. This positions Mirati as a more attractive investment opportunity within its sector. Additionally, recent stock performance has shown resilience against the Sensex, reinforcing the notion of its undervaluation.